BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1971526)

  • 1. CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection.
    Shapira-Nahor O; Golding H; Vujcic LK; Resto-Ruiz S; Fields RL; Robey FA
    Cell Immunol; 1990 Jun; 128(1):101-17. PubMed ID: 1971526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.
    Batinić D; Robey FA
    J Biol Chem; 1992 Apr; 267(10):6664-71. PubMed ID: 1551875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
    Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
    PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.
    Lanza P; Billetta R; Antonenko S; Zanetti M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11683-7. PubMed ID: 8265609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
    Kalyanaraman VS; Rausch DM; Osborne J; Padgett M; Hwang KM; Lifson JD; Eiden LE
    J Immunol; 1990 Dec; 145(12):4072-8. PubMed ID: 1701782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short synthetic peptides derived from viral proteins compete with HIV gp120 for the binding to CD4 receptors.
    Chersi A; Pugliese O; Federico A; Viora M
    Viral Immunol; 2000; 13(4):547-54. PubMed ID: 11192301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120.
    Howie SE; Cotton GJ; Heslop I; Martin NJ; Harrison DJ; Ramage R
    FASEB J; 1998 Aug; 12(11):991-8. PubMed ID: 9707171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
    Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
    Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line.
    Harouse JM; Collman RG; González-Scarano F
    J Virol; 1995 Dec; 69(12):7383-90. PubMed ID: 7494242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
    Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
    Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
    Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
    PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
    Yahi N; Sabatier JM; Nickel P; Mabrouk K; Gonzalez-Scarano F; Fantini J
    J Biol Chem; 1994 Sep; 269(39):24349-53. PubMed ID: 7929093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor.
    Yuan W; Craig S; Si Z; Farzan M; Sodroski J
    J Virol; 2004 May; 78(10):5448-57. PubMed ID: 15113923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.
    Healey D; Dianda L; Moore JP; McDougal JS; Moore MJ; Estess P; Buck D; Kwong PD; Beverley PC; Sattentau QJ
    J Exp Med; 1990 Oct; 172(4):1233-42. PubMed ID: 1698911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes.
    Clancy J; Tait-Kamradt A; Petitpas J; Manousos M; McGuirk PR; Subashi T; Watts P; Wondrack L
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2008-13. PubMed ID: 7811011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.
    Callebaut C; Blanco J; Benkirane N; Krust B; Jacotot E; Guichard G; Seddiki N; Svab J; Dam E; Muller S; Briand JP; Hovanessian AG
    J Biol Chem; 1998 Aug; 273(34):21988-97. PubMed ID: 9705340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions.
    Ohki K; Kimura T; Jones IM; Morita F; Ikuta K
    Vaccine; 1994 Mar; 12(4):343-50. PubMed ID: 8178557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.